Paul O’Riordan - Chief Executive Officer

Paul O’Riordan

Chief Executive Officer

Paul is a chartered accountant (Ireland) and holds an MBA from Harvard University. He is a former partner at McKinsey & Co and a co-founder of Synexa.

His role as CEO encompasses the overall strategic, financial and commercial management of the company. He works closely with our clients to ensure that Synexa’s approach to client service is professional, innovative and focused on bringing demonstrable value to the difficult decisions that clients need to make in new drug development.

Paul’s ambition is to build a global organisation of professional scientists that can significantly improve the productivity of new drug R&D, which he believes is a critical strategic issue facing the pharmaceutical industry and healthcare systems throughout the world.

Prof. Patrick Bouic - Principal Scientific Consultant

Prof. Patrick Bouic

Principal Scientific Consultant

Patrick is a co-founder of Synexa Life Sciences and an Extraordinary Professor of Immunology at Stellenbosch University in Cape Town.

In his role as CSO, Patrick’s main focus is to apply the latest developments in biomedical science to the challenges facing our clients and to ensure the highest quality biomarker and bioanalytical analysis across our global laboratory network. Patrick holds a PhD in immunology from the University of Claude Bernard, Lyon, France and has spent over 35 years working on the application of immunopathology to questions of human health.

His professional passion is the development of a new generation of scientists equipped to apply a more integrated understanding of human biology to the diseases and drugs with which we work.

Dr. Justin Devine - Chief Medical Officer

Dr. Justin Devine

Chief Medical Officer

Justin is a medical doctor, immunologist and pharmacologist (Stellenbosch University) and a co-founder of Synexa.

His primary focus is to understand our clients’ objectives in new drug development by designing biomarker strategies to bring real insight to the challenges of clinical development. Justin has a very deep understanding of the role that biomarkers and pharmacogenetics play in understanding the performance of a candidate drug.

He is particularly passionate about improving the drug development process by bringing innovative approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence

Emile Lens - Chief Financial & Chief Operations Officer

Emile Lens

Chief Financial & Chief Operations Officer

Emile holds a MSc degree in Economics (Erasmus University). He started his career in banking with a focus on mergers and acquisitions. As an entrepreneur, he founded two businesses and prior to joining Synexa, served as CFO and board member of a global medical device Contract Research Organisation (CRO).

Emile’s primary focus at Synexa is to drive the buy and build strategy of the company and to build a platform that is efficient, sustainable and scalable, allowing rapid international growth and facilitating the pioneering work of our scientists.

Emile is passionate about working with people and building businesses that grow into market leaders in their fields and that leave a positive footprint in terms of improving the world.

Matti Kimberg - Chief Scientific Officer

Matti Kimberg

Chief Scientific Officer

Matti is a molecular geneticist (University of Stellenbosch) and immunologist (University of Cape Town) and has more than 10 years’ experience in regulated bioanalysis and clinical biomarkers.

As CSO, his primary focus is to ensure that the execution of all work performed at Synexa is scientifically driven by the objective of generating data that is informative towards answering the specific questions being asked in the context of each study. He has a deep understanding of the principals of the regulatory framework supporting bioanalysis and applying the guidelines provided by regulators to novel analytical technologies and therapeutic modalities.

Matti is passionate about using world class science and innovation to transform the way novel therapeutics are developed, to bring them to market faster, cheaper and safer.